Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate.
President and Chief Executive Officer Joseph Oliveto called the period the company’s “first-ever quarter, or more accurately, partial quarter of sales” following the commercial launch of CARDEMYST, the brand name for etripamil. The FDA approved CARDEMYST on Dec. 12 as the first rapid-acting, self-administered prescription therapy for acute PSVT episodes in adults, according to the company.
